

TYK2 inhibitor clears psoriasis over 12 weeks

October 9 2018



(HealthDay)—Selective inhibition of TYK2 with the oral agent

BMS-986165 at doses of 3 mg daily and higher results in greater clearing of psoriasis versus placebo over 12 weeks, according to a phase 2 study published in the Oct. 4 issue of the *New England Journal of Medicine*.

Kim Papp, M.D., Ph.D., from K. Papp Clinical Research and Probit Medical Research in Peterborough, Ontario, Canada, and colleagues randomly assigned 267 patients to receive a TYK2 inhibitor, BMS-986165, orally (3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily) or [placebo](#).

The researchers found that at week 12, the percentage of patients with ≥ 75 percent reduction in the Psoriasis Area and Severity Index score was 7 percent (three of 45 patients) with placebo, 9 percent (four of 44 patients) with 3 mg of BMS-986165 every other day ($P = 0.49$ versus placebo), 39 percent (17 of 44 patients) with 3 mg daily (P

"Larger and longer-duration trials of this drug are required to determine its safety and durability of effect in [patients](#) with psoriasis," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Bristol-Myers Squibb, which manufactures BMS-986165 and funded the study.

More information: [Abstract/Full Text](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: TYK2 inhibitor clears psoriasis over 12 weeks (2018, October 9) retrieved 24 May 2024 from <https://medicalxpress.com/news/2018-10-tyk2-inhibitor-psoriasis-weeks.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.